These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33880016)

  • 1. Proxy-Reported Quality of Life and Access to Nusinersen Among Patients with Spinal Muscular Atrophy in Saudi Arabia.
    AlRuthia Y; Almuaythir GS; H Alrasheed H; Alsharif WR; Temsah MH; Alsohime F; Sales I; Alwhaibi M; Bashiri FA
    Patient Prefer Adherence; 2021; 15():729-739. PubMed ID: 33880016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The socioeconomic burden of spinal muscular atrophy in Saudi Arabia: a cross-sectional pilot study.
    Alotaibi KM; Alsuhaibani M; Al-Essa KS; Bamaga AK; Mukhtar AS; Alrumaih AM; Al-Hasinah HF; Aldossary S; Alghamdi F; Temsah MH; Abanmy N; Alwhaibi M; Asiri Y; AlRuthia Y
    Front Public Health; 2024; 12():1303475. PubMed ID: 38362212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2020 Update to Spinal Muscular Atrophy Management in Saudi Arabia.
    Bashiri FA; Temsah MH; Hundallah K; Alsohime F; AlRuthia Y
    Front Pediatr; 2021; 9():684134. PubMed ID: 34136444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life of adults with spinal muscular atrophy: insights from a nationwide patient registry in Germany.
    Landfeldt E; Leibrock B; Hussong J; Thiele S; Walter MC; Moehler E; Zemlin M; Dillmann U; Flotats-Bastardas M
    Qual Life Res; 2024 Jul; 33(7):1949-1959. PubMed ID: 38753126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Children and young adults with spinal muscular atrophy treated with nusinersen.
    Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
    Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain.
    López-Bastida J; Peña-Longobardo LM; Aranda-Reneo I; Tizzano E; Sefton M; Oliva-Moreno J
    Orphanet J Rare Dis; 2017 Aug; 12(1):141. PubMed ID: 28821278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 9. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of Life Assessment in Romanian Patients with Spinal Muscular Atrophy Undergoing Nusinersen Treatment.
    Cavaloiu B; Simina IE; Chisavu L; Vilciu C; Trăilă IA; Puiu M
    Neurol Int; 2024 Aug; 16(5):891-904. PubMed ID: 39311340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment.
    Binz C; Schreiber-Katz O; Kumpe M; Ranxha G; Siegler H; Wieselmann G; Petri S; Osmanovic A
    J Neurol; 2021 Mar; 268(3):950-962. PubMed ID: 33029682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study.
    Yao M; Ma Y; Qian R; Xia Y; Yuan C; Bai G; Mao S
    Orphanet J Rare Dis; 2021 Jan; 16(1):7. PubMed ID: 33407670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records study.
    Viscidi E; Wang N; Juneja M; Bhan I; Prada C; James D; Lallier S; Makepeace C; Laird K; Eaton S; Dilley A; Hall S
    Orphanet J Rare Dis; 2021 May; 16(1):207. PubMed ID: 33962637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
    Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
    J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
    Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
    Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular Atrophy.
    Lloyd AJ; Thompson R; Gallop K; Teynor M
    Clinicoecon Outcomes Res; 2019; 11():615-622. PubMed ID: 31749625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.